Your browser doesn't support javascript.
loading
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
Long, G V; Tykodi, S S; Schneider, J G; Garbe, C; Gravis, G; Rashford, M; Agrawal, S; Grigoryeva, E; Bello, A; Roy, A; Rollin, L; Zhao, X.
Afiliación
  • Long GV; Department of Medicine, Melanoma Institute Australia, The University of Sydney, Sydney; Department of Medical Oncology, Royal North Shore Hospital, Sydney; Department of Medical Oncology, Mater Hospital, Sydney, Australia. Electronic address: georgina.long@melanoma.org.au.
  • Tykodi SS; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle.
  • Schneider JG; Department of Hematology and Oncology, NYU Winthrop Hospital, Mineola, USA.
  • Garbe C; Department of Dermatology, University of Tübingen, Tübingen, Germany.
  • Gravis G; Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille, INSERM UMR 1068, Marseille; Department of Medical Oncology, Centre National de la Recherche Scientifique UMR 7258, Marseille; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
  • Rashford M; Oncology Clinical Development, Bristol-Myers Squibb, Princeton.
  • Agrawal S; Oncology Clinical Development, Bristol-Myers Squibb, Princeton.
  • Grigoryeva E; Oncology Clinical Development, Bristol-Myers Squibb, Princeton.
  • Bello A; Clinical Pharmacology & Pharmacometrics, Bristol-Myers Squibb, Princeton.
  • Roy A; Clinical Pharmacology & Pharmacometrics, Bristol-Myers Squibb, Princeton.
  • Rollin L; Global Biometric Sciences, Bristol-Myers Squibb, Princeton, USA.
  • Zhao X; Clinical Pharmacology & Pharmacometrics, Bristol-Myers Squibb, Princeton.
Ann Oncol ; 29(11): 2208-2213, 2018 11 01.
Article en En | MEDLINE | ID: mdl-30215677
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Antineoplásicos Inmunológicos / Nivolumab / Neoplasias Tipo de estudio: Etiology_studies Límite: Adult / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Antineoplásicos Inmunológicos / Nivolumab / Neoplasias Tipo de estudio: Etiology_studies Límite: Adult / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article